M2 PHARMA-August 16, 2017-Halloran Consulting to Act as US Regulatory Lead for Curtana Pharmaceuticals' CT-179 Orphan Drug Designation for the Treatment of Gliomas
US-based biotech, pharma, and medical device consultancy Halloran Consulting Group has assumed the role of US regulatory consultants for US-based Curtana Pharmaceuticals, the firm said.
The Food and Drug Administration granted orphan drug designation to CT-179, Curtana Pharmaceuticals' lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma in adults and pediatric high grade glioma in children.
Curtana Pharmaceuticals received orphan drug designation for CT-179 from the FDA after a review period of only 19 days.
The Food and Drug Administration (FDA) has granted orphan drug designation to CT-179, Curtana Pharmaceuticals' lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high gra de glioma in children.
Curtana is targeting Olig2, a transcription factor important to normal brain development that has been shown to be a critical oncogene controlling tumor initiation, growth, invasion, differentiation and radiation resistance.
and Chief Executive Officer, Curtana Pharmaceuticals.
Curtana Pharmaceuticals, founded in 2013, is a privately held, preclinical-stage biopharmaceutical company headquartered in Austin, Texas.
Henry Riding, prosecuting, said Wilde, of Curtana
Crescent, Norris Green, was stopped at a security check at the prison as the metal detector alarm sounded.